A 19-Gene expression signature as a predictor of survival in colorectal cancer

BMC Medical Genomics

Volumn 9, Issue 1, 2016, Pages

  Abdul Aziz, Nurul Ainin ^a   Mokhtar, Norfilza M ^b   Harun, Roslan ^a   Mollah, Md Manir Hossain ^a   Mohamed Rose, Isa ^b   Sagap, Ismail ^c   Mohd Tamil, Azmi ^b   Wan Ngah, Wan Zurinah ^a   Jamal, Rahman ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

^b DEPARTMENT OF PHARMACOLOGY   (Malaysia)

^c Hospital Kebangsaan Malaysia   (Malaysia)

Author keywords

Colorectal cancer; Microarray analysis; Real time PCR; Survivalm

Indexed keywords

NOTCH2 RECEPTOR; TRANSCRIPTOME;

ADULT; ARTICLE; AUSTRALIA; C12ORF66 GENE; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; CPXCR1 GENE; DENMARK; DOWN REGULATION; DUOX2 GENE; DUSP21 GENE; ELTDI GENE; FEMALE; FRMD6 GENE; GENE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC ASSOCIATION; GFRA4 GENE; HUMAN; HUMAN TISSUE; ITPRIP GENE; LASS6 GENE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MRPL52 GENE; NORWAY; NOTCH2 GENE; OR10H5 GENE; OSBPL9 GENE; OVERALL SURVIVAL; PDC GENE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SLC38A9 GENE; SORCS2 GENE; SPG7 GENE; TRIP13 GENE; TUMOR SUPPRESSOR GENE; UPREGULATION; BIOLOGY; COLORECTAL NEOPLASMS; DNA MICROARRAY; GENETICS; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS;

COLORECTAL NEOPLASMS; COMPUTATIONAL BIOLOGY; FEMALE; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; SURVIVAL ANALYSIS; TRANSCRIPTOME;

EID: 84986183527     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/s12920-016-0218-1     Document Type: Article

References (40)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide-sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86. doi: 10.1002/ijc.29210.
2. Wu JS. Rectal cancer staging. Clin Colon Rectal Surg. 2007;20(3):148-57. doi: 10.1055/s-2007-984859.
3. Morris EJ, Maughan NJ, Forman D, Quirke P. Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology. Gut. 2007;56(10):1419-25. doi: 10.1136/gut.2006.116830.
4. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96(19):1420-5. doi: 10.1093/jnci/djh275.
5. Ahn JB, Chung HC, Yoo NC, Roh JK, Kim NK, Suh CO, Kim GE, Seong JS, Shim WH. Efficacy of postoperative concurrent chemoradiation for resectable rectal cancer: a single institute experience. Cancer Res Treat. 2004;36(4):228-34. doi: 10.4143/crt.2004.36.4.228.
6. Marisa L, de Reynies A, Duval A, Selves J, Gaub MP, Vescovo L, Etienne-Grimaldi MC, Schiappa R, Guenot D, Ayadi M, et al. Gene expression classification of colon cancer into molecular subtypes-characterization, validation, and prognostic value. PLoS Med. 2013;10(5):e1001453. doi: 10.1371/journal.pmed.1001453.
7. Marshall JL, Haller DG, de Gramont A, Hochster HS, Lenz HJ, Ajani JA, Goldberg RM. Adjuvant therapy for stage II and III colon cancer: Consensus Report of the International Society of Gastrointestinal Oncology. Gastrointest Cancer Res. 2007;1(4):146-54.
8. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003;31:e15.
9. Wu Y, Wang X, Wu F, Huang R, Xue F, Liang G, Tao M, Cai P, Huang Y. Transcriptome profiling of the cancer, adjacent non-tumor and distant normal tissues from a colorectal cancer patient by deep sequencing. PLoS One. 2012;7(8):e41001. doi: 10.1371/journal.pone.0041001.
10. Wang Y, Jatkoe T, Zhang Y, Mutch MG, Talantov D, Jiang J, McLeod HL, Atkins D. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol. 2004;22(9):1564-71. doi: 10.1200/JCO.2004.08.186.
11. Jorissen RN, Gibbs P, Christie M, Prakash S, Lipton L, Desai J, Kerr D, Aaltonen LA, Arango D, Kruhoffer M, et al. Metastasis-Associated gene expression changes predict poor outcomes in patients with Dukes Stage B and C colorectal cancer. Clin Cancer Res. 2009;15(24):7642-51. doi: 10.1158/1078-0432.CCR-09-1431.
12. Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A, Coppola D, Kruhoffer M, Aaltonen L, Orntoft TF, et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol. 2005;23(15):3526-35. doi: 10.1200/JCO.2005.00.695.
13. Jiang WQ, Fu FF, Li YX, Wang WB, Wang HH, Jiang HP, Teng LS. Molecular biomarkers of colorectal cancer: prognostic and predictive tools for clinical practice. J Zhejiang Univ Sci B. 2012;13(9):663-75. doi: 10.1631/jzus.B1100340.
14. Agesen TH, Sveen A, Merok MA, Lind GE, Nesbakken A, Skotheim RI, Lothe RA. ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis. Gut. 2012;61(11):1560-7. doi: 10.1136/gutjnl-2011-301179.
15. Sveen A, Agesen TH, Nesbakken A, Meling GI, Rognum TO, Liestol K, Skotheim RI, Lothe RA. ColoGuidePro: a prognostic 7-gene expression signature for stage III colorectal cancer patients. Clin Cancer Res. 2012;18(21):6001-10. doi: 10.1158/1078-0432.CCR-11-3302.
16. Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C, Lopez-Doriga A, Santos C, Marijnen C, Westerga J, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol. 2011;29(1):17-24. doi: 10.1200/JCO.2010.30.1077.
17. Fung KY, Nice E, Priebe I, Belobrajdic D, Phatak A, Purins L, Tabor B, Pompeia C, Lockett T, Adams TE, et al. Colorectal cancer biomarkers: to be or not to be? Cautionary tales from a road well travelled. World J Gastroenterol. 2014;20(4):888-98. doi: 10.3748/wjg.v20.i4.888.
18. Lu AT, Salpeter SR, Reeve AE, Eschrich S, Johnston PG, Barrier AJ, Bertucci F, Buckley NS, Salpeter EE, Lin AY. Gene expression profiles as predictors of poor outcomes in stage II colorectal cancer: A systematic review and meta-analysis. Clin Colorectal Cancer. 2009;8(4):207-14. doi: 10.3816/CCC.2009.n.035.
19. Mollah MM, Mollah MN, Kishino H. Beta-empirical Bayes inference and model diagnosis of microarray data. BMC Bioinformatics. 2012;13:135. doi: 10.1186/1471-2105-13-135.
20. Gottardo R, Raftery AE, Yeung KY, Bumgarner RE. Bayesian robust inference for differential gene expression in microarrays with multiple samples. Biometrics. 2006;62(1):10-8. doi: 10.1111/j.1541-0420.2005.00397.x.
21. Mollah MN, Sultana N, Minami M, Eguchi S. Robust extraction of local structures by the minimum beta-divergence method. Neural Netw. 2010;23(2):226-38. doi: 10.1016/j.neunet.2009.11.011.
22. Mollah MN, Eguchi S. Robust QTL analysis by minimum beta-divergence method. Int J Data Min Bioinform. 2010;4(4):471-85.
23. Waldron L, Pintilie M, Tsao MS, Shepherd FA, Huttenhower C, Jurisica I. Optimized application of penalized regression methods to diverse genomic data. Bioinformatics. 2011;27(24):3399-406. doi: 10.1093/bioinformatics/btr591.
24. Thorsteinsson M, Kirkeby LT, Hansen R, Lund LR, Sorensen LT, Gerds TA, Jess P, Olsen J. Gene expression profiles in stages II and III colon cancers: application of a 128-gene signature. Int J Colorectal Dis. 2012;27(12):1579-86. doi: 10.1007/s00384-012-1517-4.
25. Webber EM, Lin JS, Evelyn PW. Oncotype DX tumor gene expression profiling in stage II colon cancer. Application: prognostic, risk prediction. PLoS Curr. 2010;2. doi: 10.1371/currents.RRN1177
26. Nguyen MN, Choi TG, Nguyen DT, Kim JH, Jo YH, Shahid M, Akter S, Aryal SN, Yoo JY, Ahn YJ, et al. RC-113 gene expression signature for predicting prognosis in patients with colorectal cancer. Oncotarget. 2015;6(31):31674-92. doi: 10.18632/oncotarget.5183.
27. Larson MG. Descriptive statistics and graphical displays. Circulation. 2006;114(1):76-81. doi: 10.1161/CIRCULATIONAHA.105.584474.
28. Le Voyer TE, Sigurdson ER, Hanlon AL, Mayer RJ, Macdonald JS, Catalano PJ, Haller DG. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol. 2003;21(15):2912-9. doi: 10.1200/JCO.2003.05.062.
29. Towner RA, Jensen RL, Colman H, Vaillant B, Smith N, Casteel R, Saunders D, Gillespie DL, Silasi-Mansat R, Lupu F, et al. ELTD1, a potential new biomarker for gliomas. Neurosurgery. 2013;72(1):77-90. doi: 10.1227/NEU.0b013e318276b29d. discussion 91.
30. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366(1):2-16. doi: 10.1016/j.gene.2005.10.018.
31. Wallgard E, Larsson E, He L, Hellstrom M, Armulik A, Nisancioglu MH, Genove G, Lindahl P, Betsholtz C. Identification of a core set of 58 gene transcripts with broad and specific expression in the microvasculature. Arterioscler Thromb Vasc Biol. 2008;28(8):1469-76. doi: 10.1161/ATVBAHA.108.165738.
32. Martin KJ, Patrick DR, Bissell MJ, Fournier MV. Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets. PLoS One. 2008;3(8):e2994. doi: 10.1371/journal.pone.0002994.
33. Hermey G, Plath N, Hubner CA, Kuhl D, Schaller HC, Hermans-Borgmeyer I. The three sorCS genes are differentially expressed and regulated by synaptic activity. J Neurochem. 2004;88(6):1470-6.
34. Rezgaoui M, Hermey G, Riedel IB, Hampe W, Schaller HC, Hermans-Borgmeyer I. Identification of SorCS2, a novel member of the VPS10 domain containing receptor family, prominently expressed in the developing mouse brain. Mech Dev. 2001;100(2):335-8.
35. Wu X, Ye Y, Rosell R, Amos CI, Stewart DJ, Hildebrandt MA, Roth JA, Minna JD, Gu J, Lin J, et al. Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. J Natl Cancer Inst. 2011;103(10):817-25. doi: 10.1093/jnci/djr075.
36. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008;14(5):518-27. doi: 10.1038/nm1764.
37. McCright B. Notch signaling in kidney development. Curr Opin Nephrol Hypertens. 2003;12(1):5-10. doi: 10.1097/01.mnh.0000049802.69874.c0.
38. Lemaigre F, Zaret KS. Liver development update: new embryo models, cell lineage control, and morphogenesis. Curr Opin Genet Dev. 2004;14(5):582-90. doi: 10.1016/j.gde.2004.08.004.
39. Chu D, Zhang Z, Zhou Y, Wang W, Li Y, Zhang H, Dong G, Zhao Q, Ji G. Notch1 and Notch2 have opposite prognostic effects on patients with colorectal cancer. Ann Oncol. 2011;22(11):2440-7. doi: 10.1093/annonc/mdq776.
40. Lenehan PF, Boardman LA, Riegert-Johnson D, De Petris G, Fry DW, Ohrnberger J, Heyman ER, Gerard B, Almal AA, Worzel WP. Generation and external validation of a tumor-derived 5-gene prognostic signature for recurrence of lymph node-negative, invasive colorectal carcinoma. Cancer. 2012;118(21):5234-524. doi: 10.1002/cncr.27628.